Health sciences company PreveCeutical Medical Inc (CSE:PREV) (OTCQB:PRVCF) (FSE:18H) stated on Wednesday that it plans to launch the clinical trials of its cannabinoid Sol-gel to reduce the possibility of contracting coronavirus infections.
In conjunction with the COVID-19 Sol-Gel clinical programme, the company has retained Veristat, a global clinical research organization (CRO) located in Massachusetts, USA, to assist with planning the clinical trial process and writing the required protocols.
Pursuant to the consulting agreement, Veristat will provide services to design and develop PreveCeutical COVID-19 Sol-Gel clinical programme and required protocol.
Johnson & Johnson initiates final study of single-shot COVID-19 vaccine in 60,000 volunteers
Bridge Biotherapeutics confirms safety and efficacy profiles of BBT-401
Fujifilm reports Avigan effective in Phase-3 trial for treatment of COVID-19 patients
Sinovac Starts Phase III Clinical Trials for COVID-19 Vaccine Candidate in Turkey
Canada Exercises Increased Option for 20m Doses of Moderna mRNA Vaccine Against COVID-19
Siolta Therapeutics Raises USD 30m Series B for the Prevention and Treatment of Allergic Diseases